Izotropic Corporation (IZOZF)
USD 0.03
(-10.45%)
USD 0.03
(-10.45%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -1.56 Million CAD | 70.67% |
| 2023 | -5.34 Million CAD | 19.23% |
| 2022 | -6.61 Million CAD | -32.89% |
| 2021 | -4.97 Million CAD | -330.52% |
| 2020 | -1.15 Million CAD | -190.02% |
| 2019 | -398.53 Thousand CAD | 43.5% |
| 2018 | -705.4 Thousand CAD | -870.45% |
| 2017 | -72.68 Thousand CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -245.14 Thousand CAD | 64.33% |
| 2024 FY | -1.69 Million CAD | 68.19% |
| 2024 Q4 | -337.58 Thousand CAD | -37.71% |
| 2024 Q1 | -429.9 Thousand CAD | 64.52% |
| 2024 Q2 | -687.18 Thousand CAD | -59.85% |
| 2023 Q3 | -1.91 Million CAD | -48.22% |
| 2023 Q4 | -1.21 Million CAD | 36.81% |
| 2023 FY | -5.34 Million CAD | 19.23% |
| 2023 Q1 | -964.27 Thousand CAD | 40.58% |
| 2023 Q2 | -1.29 Million CAD | -34.15% |
| 2022 Q2 | -2.53 Million CAD | -106.71% |
| 2022 Q1 | -1.22 Million CAD | 35.73% |
| 2022 FY | -6.61 Million CAD | -32.89% |
| 2022 Q4 | -1.62 Million CAD | -30.43% |
| 2022 Q3 | -1.24 Million CAD | 50.85% |
| 2021 Q3 | -2.37 Million CAD | -538.67% |
| 2021 Q2 | -371.31 Thousand CAD | 17.27% |
| 2021 FY | -4.97 Million CAD | -330.52% |
| 2021 Q1 | -448.81 Thousand CAD | 25.83% |
| 2021 Q4 | -1.9 Million CAD | 19.66% |
| 2020 FY | -1.15 Million CAD | -190.02% |
| 2020 Q4 | -605.14 Thousand CAD | -143.13% |
| 2020 Q3 | -248.89 Thousand CAD | -60.18% |
| 2020 Q1 | -146.42 Thousand CAD | -5.64% |
| 2020 Q2 | -155.38 Thousand CAD | -6.12% |
| 2019 Q1 | -87.91 Thousand CAD | 43.32% |
| 2019 Q2 | -94.39 Thousand CAD | -7.37% |
| 2019 Q4 | -138.6 Thousand CAD | -78.55% |
| 2019 FY | -398.53 Thousand CAD | 43.5% |
| 2019 Q3 | -77.62 Thousand CAD | 17.76% |
| 2018 Q1 | -72.07 Thousand CAD | -209280.08% |
| 2018 Q2 | -409.22 Thousand CAD | -467.76% |
| 2018 Q3 | -68.98 Thousand CAD | 83.14% |
| 2018 Q4 | -155.11 Thousand CAD | -124.85% |
| 2018 FY | -705.4 Thousand CAD | -870.45% |
| 2017 Q1 | -14.83 CAD | 0.0% |
| 2017 Q4 | -34.42 CAD | -126.32% |
| 2017 FY | -72.68 Thousand CAD | 0.0% |
| 2017 Q2 | -22.10 CAD | -49.03% |
| 2017 Q3 | -15.21 CAD | 31.19% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| American Bio Medica Corporation | -1.24 Million USD | -26.112% |
| Arrayit Corporation | -3.62 Million USD | 56.762% |
| Atlantic International Corp. | -5.73 Million USD | 72.677% |
| Biocept, Inc. | -31.98 Million USD | 95.103% |
| Bioqual, Inc. | -19.63 Thousand USD | -7875.929% |
| CardioGenics Holdings Inc | -772.14 Thousand USD | -102.853% |
| DermTech, Inc. | -103.73 Million USD | 98.49% |
| Global WholeHealth Partners Corporation | - USD | Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.48 Billion USD | 100.063% |
| HTG Molecular Diagnostics, Inc. | -20.82 Million USD | 92.48% |
| iMD Companies, Inc. | -175.44 Thousand USD | -792.761% |
| IDenta Corp. | -1499.00 USD | -104390.527% |
| Interpace Biosciences, Inc. | 2.8 Million USD | 155.86% |
| Integrative Health Technologies, Inc. | 38.69 Thousand USD | 4148.367% |
| InVitro International | -25.33 Thousand USD | -6081.432% |
| Lumos Diagnostics Holdings Limited | -7.12 Million USD | 78.007% |
| Many Bright Ideas Technologies Inc. | -58.11 Thousand USD | -2595.335% |
| Medical Imaging Corp. | -819.48 Thousand USD | -91.135% |
| NovelStem International Corp. | -3.52 Million USD | 55.576% |
| Optigenex Inc. | 1.39 Million USD | 212.617% |
| PharmChem, Inc. | 973.14 Thousand USD | 260.953% |
| Proteome Sciences plc | -1.62 Million USD | 3.374% |
| Response Genetics, Inc | -21.37 Million USD | 92.673% |
| Rennova Health, Inc. | -1.4 Million USD | -11.123% |
| RushNet, Inc. | -684.7 Thousand USD | -128.757% |
| ScreenPro Security Inc. | -2.59 Million USD | 39.581% |
| Stella Diagnostics Inc. | -11.42 Million USD | 86.293% |
| StageZero Life Sciences Ltd. | -7.74 Million USD | 79.781% |
| Todos Medical Ltd. | -9.74 Million USD | 83.932% |